214 related articles for article (PubMed ID: 34763703)
1. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study.
Chan SCW; Chung HY; Lau CS; Li PH
Ann Clin Microbiol Antimicrob; 2021 Nov; 20(1):78. PubMed ID: 34763703
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
3. Cytomegaloviral or
Sun YS; Huang DF; Lin FC; Hsu CK; Sun IT; Chang SC; Tsai CY; Lai CC
J Rheumatol; 2019 Mar; 46(3):251-258. PubMed ID: 30504509
[TBL] [Abstract][Full Text] [Related]
4. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
5. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study.
Tadros S; Teichtahl AJ; Ciciriello S; Wicks IP
Semin Arthritis Rheum; 2017 Jun; 46(6):804-809. PubMed ID: 27814896
[TBL] [Abstract][Full Text] [Related]
6. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.
Basiaga ML; Ross ME; Gerber JS; Ogdie A
J Pediatric Infect Dis Soc; 2018 Dec; 7(4):283-289. PubMed ID: 28992298
[TBL] [Abstract][Full Text] [Related]
8. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis.
Matraiah EH; Olisaka N; Philipos M; Walbaum D; Dospinescu P; Fluck N; Basu N; Kidder D
Clin Rheumatol; 2018 Jul; 37(7):1991-1996. PubMed ID: 29808456
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.
Hsu HC; Chang YS; Hou TY; Chen LF; Hu LF; Lin TM; Chiou CS; Tsai KL; Lin SH; Kuo PI; Chen WS; Lin YC; Chen JH; Chang CC
Clin Rheumatol; 2021 Sep; 40(9):3755-3763. PubMed ID: 33646447
[TBL] [Abstract][Full Text] [Related]
11. Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus.
Boone B; Lazaroff SM; Wheless L; Wolfe RM; Barnado A
Semin Arthritis Rheum; 2022 Dec; 57():152106. PubMed ID: 36279805
[TBL] [Abstract][Full Text] [Related]
12. Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab.
Park JW; Curtis JR; Choi SR; Kim MJ; Ha YJ; Kang EH; Lee YJ; Lee EB
Arthritis Rheumatol; 2023 Nov; 75(11):2036-2044. PubMed ID: 37096489
[TBL] [Abstract][Full Text] [Related]
13. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center.
Huang L; Fu Q; Ye Y; Lin Y; Yan Q; Chen S
Arthritis Res Ther; 2021 Sep; 23(1):232. PubMed ID: 34481528
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide.
Nettleton E; Sattui SE; Wallace Z; Putman M
Arthritis Care Res (Hoboken); 2024 Feb; 76(2):288-294. PubMed ID: 37643919
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.
Zhang Y; Zheng Y
Rheumatol Int; 2014 Dec; 34(12):1765-71. PubMed ID: 24948376
[TBL] [Abstract][Full Text] [Related]
16. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
17. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
18. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
[TBL] [Abstract][Full Text] [Related]
19. Critical appraisal of the quality and content of clinical practice guidelines for pneumocystis jiroveci pneumonia (PJP) prophylaxis using the AGREE II instrument.
Yu Y; Yang H; Yu X; Hu X; Wang W; Yang X; Liu H; Ren L; Zhang X; Feng X; Liu L
J Clin Pharm Ther; 2020 Dec; 45(6):1325-1333. PubMed ID: 32710453
[TBL] [Abstract][Full Text] [Related]
20. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
